U.S. Personal Products Stock News

Thermon Group Holdings (THR) has drawn investor attention after its recent share performance, including a return of 17.0% over the past month and 41.3% over the past 3 months, prompting closer scrutiny of its fundamentals. See our latest analysis for Thermon Group Holdings. The recent 17.0% 1 month share price return and 41.3% 3 month share price return have come after a strong run in total shareholder returns, with a 75.2% 1 year total shareholder return suggesting momentum has been building...

Why Oddity Tech Stock Is Back on Investors’ Radar Interest in Oddity Tech (NasdaqGM:ODD) picked up after Conestoga Capital Advisors highlighted the company in its fourth quarter 2025 investor letter, pointing to rapid scaling, revenue growth, and solid operating margins. See our latest analysis for Oddity Tech. Despite the positive attention from Conestoga, Oddity Tech’s recent trading has been choppy. The 7 day share price return is 6.48%, but the 30 day share price return shows a 15.58%...

CarGurus, NasdaqGS:CARG, has authorized a new $250 million share repurchase program. The company is sharpening its focus on its core marketplace and international growth after winding down CarOffer. Management highlighted strong revenue, record retention, and faster dealer acquisition, including outside the US. CarGurus, trading at $27.86, sits at an interesting crossroads, with a 3-year return of 63.4% and a 5-year return of 5.5%. In the shorter term, the stock is down 18.1% over the past...

If you are wondering whether Zeta Global Holdings is attractively priced or just looks cheap on the surface, this article breaks down what the current share price really implies. The stock closed at US$14.98, with returns of a 3.1% decline over 7 days, a 31.1% decline over 30 days, a 24.8% decline year to date and a 30.7% decline over the past year, while the 3 year return stands at 37.2%. Recent coverage has focused on how Zeta Global is positioning its software and data offerings within...

CDW Corporation (NasdaqGS:CDW) is reorganizing its operations into three customer-focused segments: Commercial, Government, and Education. The company has entered into a new credit agreement that increases its borrowing capacity. CDW has filed a universal shelf registration, giving it the ability to issue a range of securities in the future if it chooses. CDW is a large IT solutions and services provider that sits at the intersection of hardware, software, and cloud needs for business,...

Garmin (NYSE:GRMN) has introduced the Garmin Catalyst 2, a motorsports device aimed at track drivers seeking advanced coaching tools. The company has also launched the zumo XT3, a motorcycle focused GPS unit designed for riders who want purpose built navigation and performance features. For investors watching NYSE:GRMN, these launches sit squarely in Garmin's core focus on specialized GPS hardware and performance oriented devices. By targeting motorsports drivers and motorcyclists, the...

If you have been wondering whether CenterPoint Energy's current share price lines up with its underlying value, this article explains what the numbers are really saying about the stock. CenterPoint Energy recently closed at US$42.89, with returns of 0.9% over 7 days, 10.6% over 30 days, 10.7% year to date, 28.3% over 1 year, 62.9% over 3 years and 148.5% over 5 years. These figures may have some investors reassessing both its growth potential and its risk profile. Recent coverage around...

If you are wondering whether Medline’s current share price truly reflects its potential, you are not alone. This article is built to help you make sense of what the numbers are saying about its value. Medline shares last closed at US$49.64, with returns of 11.4% over the past 7 days, 7.9% over the past 30 days, and 22.2% year to date, which naturally raises questions about how much of the story is already in the price. Recent coverage around Medline has focused on its role in the healthcare...

Market context and recent performance Cencora (COR) has drawn attention after its recent close at US$366.03. This has prompted investors to reassess how its current valuation aligns with return trends over the past month, past 3 months, and longer periods. See our latest analysis for Cencora. Recent trading has kept Cencora’s share price near US$366.03, with a 3.55% 1 month share price return and an 8.01% year to date share price return. Its 1 year total shareholder return of 50.94% points to...

Wondering if Wynn Resorts at around US$107 is offering value today or if the easy money has already been made? This article is designed to help you frame that question clearly. The stock is down about 5.4% over the last week and 5.5% over the last month, yet it still shows a 20.1% return over the past year. That combination can change how you think about both upside potential and risk. Recent coverage has focused on Wynn Resorts as a major casino and resort operator with exposure to both...

Earlier in February 2026, Bank of Hawaii Corporation disclosed that Director Robert W. Wo Jr., through the Robert Ching Wo Trust 1985, sold 5,000 indirectly held common shares, while the bank also confirmed its CEO plans to retire at the end of March 2026. The combination of leadership transition and insider share sale has sharpened investor focus on how Bank of Hawaii will manage succession and governance continuity. We’ll now examine how the CEO’s planned retirement may influence Bank of...

For investors considering whether Berkshire Hathaway remains a sensible place to put long term capital, or whether the current price already reflects its strengths, this article walks through what the numbers are really saying about value today. The stock most recently closed at US$740,200, with returns of a 1.5% decline over 7 days, 2.7% over 30 days, a 0.5% decline year to date, a 1% decline over 1 year, 60.2% over 3 years, and 95.9% over 5 years, a mix that raises fair questions about...

Earlier in February, Travel + Leisure Co. reported higher quarterly and full-year revenue but moved from quarterly net income to a US$61 million net loss, while also recommending a first-quarter 2026 dividend of US$0.60 per share and completing a long-running US$6.89 billion share repurchase program. At the same time, the company authorized a new US$750 million buyback, signaling continued focus on returning cash to shareholders even as earnings softened. We’ll now examine how this...

Q4 earnings beat and AI focus put Progress Software (PRGS) in the spotlight Progress Software (PRGS) has moved back into focus after a strong Q4 earnings beat, with management highlighting AI driven growth plans, tighter cost controls, and revenue opportunities across its AI powered software platforms. See our latest analysis for Progress Software. At a share price of US$40.84, Progress Software has seen strong short term momentum, with a 7 day share price return of 11.8%, even though its 1...

In February 2026, Ziff Davis, Inc. reported fourth-quarter 2025 results showing sales of US$406.71 million and net income of US$0.37 million, with full-year 2025 sales of US$1.45 billion and net income of US$47.35 million, both compared with slightly higher profit levels a year earlier. The sharp year-on-year drop in quarterly earnings per share, from US$1.43 diluted to US$0.01, contrasts with modest full-year revenue growth and raises questions about cost pressures, one-off items, or...

Event overview and why it matters for St. Joe St. Joe (JOE) has broken ground on a third sales center for its Watersound Real Estate brokerage at Watersound West Bay Center, expanding its presence in high-traffic Gulf Coast communities. The new location is planned to sit alongside Watersound Title Agency and Watersound Insurance Agency, reflecting the company’s push toward integrated, asset-light services that can support recurring revenue tied to its residential communities. See our latest...

Earlier this week, Bruker Corporation unveiled major upgrades across its spatial biology and proteomics portfolio, including the PaintScape 3D genome visualization platform, the CellScape XR spatial proteomics system, Functional Proteomics 2.0 workflows on timsOmni, and a new Spatial Biology Center of Excellence with the University of Glasgow. Together, these launches and collaborations deepen Bruker’s presence in high-content multiomics and translational research tools, potentially...

In February 2026, Belden Inc. reported past fourth-quarter 2025 sales of US$720.12 million and net income of US$67.89 million, alongside full-year 2025 sales of US$2.72 billion and net income of US$237.52 million, while outlining first-quarter 2026 guidance and confirming continued share repurchases. The combination of higher earnings, ongoing buybacks totaling US$154.91 million for 1.35 million shares, and an active M&A agenda underlines Belden’s focus on long-term value creation. With...

Why CMS Energy (CMS) is on investors’ radar today CMS Energy (CMS) has not been driven by a single headline event recently, but its recent share performance and fundamentals give investors several concrete data points to weigh. The stock’s recent returns span a mixed short term picture and a stronger longer term track record. CMS is up 0.6% over the past day, has slipped about 0.6% over the past week, and is higher by 7.9% over the past month. Looking further out, the total return stands at...

Rollins, Inc. recently reported higher fourth-quarter and full-year 2025 earnings, continued to signal a healthy M&A pipeline, and earlier this month presented its outlook at Barclays’ 43rd Annual Industrial Select Conference in Miami. Management’s emphasis on recurring revenue, disciplined acquisitions, and confidence in funding further deals after investing almost US$900 million over three years highlights how central M&A has become to Rollins’ growth ambitions. We’ll now examine how...

Plexus overview after recent trading move Plexus (PLXS) has drawn fresh attention after a recent move in its share price, with the stock last closing at $197.55. That level reflects a 1 day return of about a 0.5% decline and a 7 day return of roughly a 1.9% decline. See our latest analysis for Plexus. While Plexus has seen a modest 1 day share price pullback and a softer 7 day share price return, the 30 day share price return of 13.52% and 90 day share price return of 38.52% sit alongside a 1...

Neurocrine Biosciences (NBIX) is back in focus after reporting fourth quarter and full year 2025 earnings, alongside fresh 2026 sales guidance for INGREZZA and optimistic commentary around its late stage pipeline. See our latest analysis for Neurocrine Biosciences. At a latest share price of US$128.38, Neurocrine Biosciences has seen short term share price pressure, with a 30 day share price return of a 5.73% decline and a 90 day share price return of a 10.56% decline. However, a 1 year total...

Why ICU Medical is back on investors’ radar ICU Medical (ICUI) has moved back into focus after resolving a longstanding FDA warning letter tied to its Smiths Medical business and posting fourth quarter results with adjusted earnings above analyst expectations, along with 2026 guidance that came in ahead of consensus. The company paired these updates with detailed 2026 earnings guidance, giving investors clearer visibility into expected GAAP net income of US$26 million to US$44 million and...

On 17 February 2026, Bernstein Litowitz Berger & Grossmann LLP filed a class action alleging that Express Scripts, Cigna, and Evernorth diverted billions in drug rebates to a Swiss affiliate, Ascent, using disguised “fees” and formulary decisions that allegedly favored higher-paying drug manufacturers over lower-cost alternatives. The lawsuit directly challenges how Express Scripts and its parent Cigna structure and disclose PBM rebate economics, raising complex questions about fiduciary...